Research and Markets: Launch of New Targeted Therapeutics Will Drive Market Growth During the Forecast Period 2010-2017

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/a2e214/oncology_therapeut) has announced the addition of the "Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development" report to their offering.

GBI Research, the leading business intelligence provider, has released its latest research, "Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development," which provides insights into the global oncology therapeutics market and market forecasts until 2017. The report provides an in-depth analysis of major oncology indications, which includes breast cancer, colorectal cancer, Non-Hodgkin's Lymphoma (NHL), Non-Small Cell Lung Cancer (NSCLC), prostate cancer, ovarian cancer, cervical cancer and head and neck cancer. The report also includes insights into the oncology therapeutics R&D pipeline. It analyzes the competitive landscape in the oncology therapeutics market through analysis of M&A, licensing and co-development deals. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research's analysis of the oncology therapeutics market shows that the drug discovery and development process in the oncology sector is driven by the unmet needs of patients. The unmet need for most of the cancers is the availability of safe and effective targeted drugs to treat the late stages of the disease, when patients often stop responding to chemotherapy. The presence of many targeted therapeutics that treat late-stage cancers in Phase III product pipelines supports this point.

Launch of New Targeted Therapeutics will Drive Market Growth during the Forecast Period 2010-2017

Product pipelines for all the therapeutic indications have targeted therapeutics in Phase III. The launch of some of the targeted therapeutics is expected to drive growth in the oncology therapeutics market during the forecast period 2010-2017.

Read more inside Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development

Companies Mentioned:

  • F. Hoffmann-La Roche
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Sanofi
  • Novartis AG

For more information visit http://www.researchandmarkets.com/research/a2e214/oncology_therapeut



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.